Litigation

Recent Posts

Alabama High Court Says Wyeth Can Be Liable For Injuries Caused By Generic Drug
Posted on 11 Jan 2013 by Tom Moylan

MONTGOMERY, Ala. - (Mealey's) An 8-1 majority of the Alabama Supreme Court on Jan. 11 ruled that Wyeth can be held liable for failing to warn doctors about the risk of long-term use of Reglan if a patient was injured by metoclopramide, the generic... Read More

Tags: Wyeth , Danny Weeks , Pfizer Inc. , tardive dyskinesia , Alabama Supreme Court , Schwarz Pharma Inc. , Litigation , Actavis Elizabeth LLC , generic drugs , metoclopramide , Wyeth v. Danny Weeks , Reglan , Teva Pharmaceuticals USA

3rd Circuit Says Design Defect Claims For Generic Fosamax Are Preempted
Posted on 1 May 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Strict liability design defect claims involving generic versions of the osteoporosis drug Fosamax are preempted by federal law despite plaintiffs’ attempts to narrow U.S. Supreme Court case law, a panel of the... Read More

Tags: Third Circuit , preemption , In Re: Fosamax [Alendronate Sodium] Products Liability Litigation [No. II] , Mylan Pharmaceuticals Inc. , Sun Pharmaceutical Industries Inc. , Apotex Corp. , Litigation , osteoporosis drug , multidistrict litigation , Merck Sharp & Dohme Corp. , Fosamax , U.S. Supreme Court , MDL , torts , Watson Pharmaceuticals Inc. , Teva Pharmaceuticals USA , Barr Pharmaceuticals Inc.